Advertisement

Dried blood spot testing for estimation of renal function and analysis of metformin and sitagliptin concentrations in diabetic patients: a cross-sectional study

  • Maike Scherf-Clavel
  • Edwin Albert
  • Stephan Zieher
  • Anagnostis Valotis
  • Thomas Hickethier
  • Petra HöggerEmail author
Pharmacokinetics and Disposition
First Online:
  • 71 Downloads

Abstract

Purpose

Dried blot spot (DBS) analysis of drugs or clinical parameters offers many advantages. We investigated the feasibility of using DBS for analysis of anti-diabetic drugs concomitantly with the estimated creatinine clearance (Clcrea).

Methods

The cross-sectional study involved physicians in an enabling analysis with 70 diabetic patients and community pharmacists in a field investigation with 84 participants. All 154 DBS samples were analyzed for creatinine, metformin, and sitagliptin.

Results

The diabetic patients revealed of a wide range of age (32–88 years), BMI values (19.8–54.7 kg/m2), and extent of polypharmacotherapy (1–21 drugs). A correlation factor to convert capillary blood creatinine from DBS into plasma concentrations was determined. Patients’ Clcrea ranged from 21.6–155.9 mL/min. The results indicated statistically significant correlations (p < 0.05) between the use of two or three particular drug classes (diuretics, NSAIDs, renin-angiotensin system blockers) and a decreased renal function. DBS concentrations of metformin ranged between 0.23–4.99 μg/mL. The estimated elimination half-life (t ½) of metformin was 11.9 h in patients with a ClCrea higher than 60 mL/min and 18.5 h for diabetics with lower ClCrea. Sitagliptin capillary blood concentrations ranged between 11.12–995.6 ng/mL. Calculated t ½ of sitagliptin were 8.4 h and 13.0 h in patients with a ClCrea above and below 60 mL/min, respectively.

Conclusions

DBS allow for the analysis of concentrations of predominantly renally eliminated drugs and community pharmacists can provide a valuable contribution to DBS sampling.

Keywords

Metformin Sitagliptin Creatinine Clinical study Dried blood spots Capillary blood 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgements

The authors would like to thank the patients and all 14 engaged community pharmacies for their participation in this study. The excellent technical assistance of Sabrina Rösel (office of Drs. Albert and Zieher) is gratefully acknowledged.

Compliance with ethical standards

Patients were recruited and enrolled in the study after written informed consent. The study was approved by the ethics committee of the Medical Faculty of the University of Würzburg (reference number 287/14) and the Freiburg Ethics Committee International (FEKI) and registered by ISRCTN (ISRCTN14518136).

Conflict of interests

The authors declare that they have no conflict of interest.

Supplementary material

228_2019_2637_MOESM1_ESM.docx (283 kb)
Figure S1 (DOCX 283 kb)

References

  1. 1.
    Enderle Y, Foerster K, Burhenne J (2016) Clinical feasibility of dried blood spots: analytics, validation, and applications. J Pharm Biomed Anal 130:231–243.  https://doi.org/10.1016/j.jpba.2016.06.026 CrossRefGoogle Scholar
  2. 2.
    Wilhelm AJ, den Burger JC, Swart EL (2014) Therapeutic drug monitoring by dried blood spot: progress to date and future directions. Clin Pharmacokinet 53(11):961–973.  https://doi.org/10.1007/s40262-014-0177-7 CrossRefGoogle Scholar
  3. 3.
    Martial LC, Aarnoutse RE, Schreuder MF, Henriet SS, Bruggemann RJ, Joore MA (2016) Cost evaluation of dried blood spot home sampling as compared to conventional sampling for therapeutic drug monitoring in children. PLoS One 11(12):e0167433.  https://doi.org/10.1371/journal.pone.0167433 CrossRefGoogle Scholar
  4. 4.
    Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16(1):31–41CrossRefGoogle Scholar
  5. 5.
    Drenth-van Maanen AC, Jansen PA, Proost JH, Egberts TC, van Zuilen AD, van der Stap D, van Marum RJ (2013) Renal function assessment in older adults. Br J Clin Pharmacol 76(4):616–623.  https://doi.org/10.1111/bcp.12199 Google Scholar
  6. 6.
    Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, Furlong TJ, Greenfield JR, Greenup LC, Kirkpatrick CM, Ray JE, Timmins P, Williams KM (2011) Clinical pharmacokinetics of metformin. Clin Pharmacokinet 50(2):81–98.  https://doi.org/10.2165/11534750-000000000-00000 CrossRefGoogle Scholar
  7. 7.
    Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK (2014) Metformin in patients with type 2 diabetes and kidney disease: a systematic review. Jama 312(24):2668–2675.  https://doi.org/10.1001/jama.2014.15298 CrossRefGoogle Scholar
  8. 8.
    DeFronzo R, Fleming GA, Chen K, Bicsak TA (2016) Metformin-associated lactic acidosis: current perspectives on causes and risk. Metabolism 65(2):20–29.  https://doi.org/10.1016/j.metabol.2015.10.014 CrossRefGoogle Scholar
  9. 9.
    Lalau JD, Lacroix C (2003) Measurement of metformin concentration in erythrocytes: clinical implications. Diabetes Obes Metab 5(2):93–98CrossRefGoogle Scholar
  10. 10.
    Lalau JD, Lemaire-Hurtel AS, Lacroix C (2011) Establishment of a database of metformin plasma concentrations and erythrocyte levels in normal and emergency situations. Clin Drug Investig 31(6):435–438CrossRefGoogle Scholar
  11. 11.
    Scheen AJ (2010) Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin. Expert Opin Drug Metab Toxicol 6(10):1265–1276.  https://doi.org/10.1517/17425255.2010.513699 CrossRefGoogle Scholar
  12. 12.
    Scherf-Clavel M, Högger P (2015) Analysis of metformin, sitagliptin and creatinine in human dried blood spots. J Chromatogr B Anal Technol Biomed Life Sci 997:218–228.  https://doi.org/10.1016/j.jchromb.2015.06.014 CrossRefGoogle Scholar
  13. 13.
    Scheen AJ (1996) Clinical pharmacokinetics of metformin. Clin Pharmacokinet 30(5):359–371CrossRefGoogle Scholar
  14. 14.
    Piccoli GB, Grassi G, Cabiddu G, Nazha M, Roggero S, Capizzi I, De Pascale A, Priola AM, Di Vico C, Maxia S, Loi V, Asunis AM, Pani A, Veltri A (2015) Diabetic kidney disease: a syndrome rather than a single disease. Rev Diabet Stud 12(1–2):87–109.  https://doi.org/10.1900/RDS.2015.12.87 CrossRefGoogle Scholar
  15. 15.
    Pazhayattil GS, Shirali AC (2014) Drug-induced impairment of renal function. Int J Nephrol Renov Dis 7:457–468.  https://doi.org/10.2147/IJNRD.S39747 Google Scholar
  16. 16.
    Loboz KK, Shenfield GM (2005) Drug combinations and impaired renal function -- the 'triple whammy'. Br J Clin Pharmacol 59(2):239–243.  https://doi.org/10.1111/j.0306-5251.2004.2188.x CrossRefGoogle Scholar
  17. 17.
    Onuigbo MA (2013) The nephrotoxic "triple whammy" of combining diuretics, ACE inhibitors, and NSAIDs. BMJ 346:f678.  https://doi.org/10.1136/bmj.f678 CrossRefGoogle Scholar
  18. 18.
    Prieto-Garcia L, Pericacho M, Sancho-Martinez SM, Sanchez A, Martinez-Salgado C, Lopez-Novoa JM, Lopez-Hernandez FJ (2016) Mechanisms of triple whammy acute kidney injury. Pharmacol Ther 167:132–145.  https://doi.org/10.1016/j.pharmthera.2016.07.011 CrossRefGoogle Scholar
  19. 19.
    Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S (2013) Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ 346:e8525.  https://doi.org/10.1136/bmj.e8525 CrossRefGoogle Scholar
  20. 20.
    Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 130(6):461–470CrossRefGoogle Scholar
  21. 21.
    den Burger JC, Wilhelm AJ, Chahbouni AC, Vos RM, Sinjewel A, Swart EL (2015) Haematocrit corrected analysis of creatinine in dried blood spots through potassium measurement. Anal Bioanal Chem 407(2):621–627.  https://doi.org/10.1007/s00216-014-8291-9 CrossRefGoogle Scholar
  22. 22.
    Koop DR, Bleyle LA, Munar M, Cherala G, Al-Uzri A (2013) Analysis of tacrolimus and creatinine from a single dried blood spot using liquid chromatography tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 926:54–61CrossRefGoogle Scholar
  23. 23.
    Keevil BG (2011) The analysis of dried blood spot samples using liquid chromatography tandem mass spectrometry. Clin Biochem 44(1):110–118CrossRefGoogle Scholar
  24. 24.
    Koster RA, Greijdanus B, Alffenaar JW, Touw DJ (2015) Dried blood spot analysis of creatinine with LC-MS/MS in addition to immunosuppressants analysis. Anal Bioanal Chem 407(6):1585–1594.  https://doi.org/10.1007/s00216-014-8415-2 CrossRefGoogle Scholar
  25. 25.
    Cohen E, Nardi Y, Krause I, Goldberg E, Milo G, Garty M, Krause I (2014) A longitudinal assessment of the natural rate of decline in renal function with age. J Nephrol 27(6):635–641.  https://doi.org/10.1007/s40620-014-0077-9 CrossRefGoogle Scholar
  26. 26.
    Bardin C, Nobecourt E, Larger E, Chast F, Treluyer JM, Urien S (2012) Population pharmacokinetics of metformin in obese and non-obese patients with type 2 diabetes mellitus. Eur J Clin Pharmacol 68(6):961–968CrossRefGoogle Scholar
  27. 27.
    Duong JK, Kroonen M, Kumar SS, Heerspink HL, Kirkpatrick CM, Graham GG, Williams KM, Day RO (2017) A dosing algorithm for metformin based on the relationships between exposure and renal clearance of metformin in patients with varying degrees of kidney function. Eur J Clin Pharmacol 73(8):981–990.  https://doi.org/10.1007/s00228-017-2251-1 CrossRefGoogle Scholar
  28. 28.
    Dissanayake AM, Wheldon MC, Hood CJ (2018) Pharmacokinetics of metformin in patients with chronic kidney disease stage 4 and metformin-naive type 2 diabetes. Pharmacol Res Perspect 6(5):e00424.  https://doi.org/10.1002/prp2.424 CrossRefGoogle Scholar
  29. 29.
    Chen X, Zhao Q, Zhang J, Liu T, Jiang J, Hu P (2016) An open-label, multiple-dose study to assess the pharmacokinetics and tolerability of sitagliptin/metformin fixed-dose combination (FDC) tablet in healthy Chinese adult subjects. Int J Clin Pharmacol Ther 54(9):705–711.  https://doi.org/10.5414/CP202646 CrossRefGoogle Scholar
  30. 30.
    Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, Tanen M, Wang AQ, Chen L, Winchell G, Davies MJ, Ramael S, Wagner JA, Herman GA (2006) Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 28(1):55–72.  https://doi.org/10.1016/j.clinthera.2006.01.015 CrossRefGoogle Scholar
  31. 31.
    Radley A, Melville K, Tait J, Stephens B, Evans JMM, Dillon JF (2017) A quasi-experimental evaluation of dried blood spot testing through community pharmacies in the Tayside region of Scotland. Frontline Gastroenterol 8(3):221–228.  https://doi.org/10.1136/flgastro-2016-100776 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Maike Scherf-Clavel
    • 1
  • Edwin Albert
    • 2
  • Stephan Zieher
    • 2
  • Anagnostis Valotis
    • 3
  • Thomas Hickethier
    • 4
  • Petra Högger
    • 1
    Email author
  1. 1.Institut für Pharmazie und LebensmittelchemieUniversität WürzburgWürzburgGermany
  2. 2.Gemeinschaftspraxis, Ärzte für Allgemeinmedizin, DiabetologieMarktheidenfeldGermany
  3. 3.Stabsstelle MedizinsicherheitUniversitätsklinikum WürzburgWürzburgGermany
  4. 4.Stabsstelle BetriebsarztUniversitätsklinikum WürzburgWürzburgGermany

Personalised recommendations

Cite article

Buy options